The Robot That Navigates Blood Vessels
Slice of Healthcare Team
09/02/2025
Introduction
In a world where surgical robots are mostly built like industrial arms, Stereotaxis is quietly building something stranger and more powerful.
A Robot Designed for the Human Body
Stereotaxis builds a robotic system for minimally invasive heart procedures. Unlike traditional surgical robots that mimic a surgeon’s hands, Stereotaxis guides flexible, hair-thin catheters through the body using magnetic fields. It’s the only commercial robot navigating the vast and mostly untouched field of endovascular surgery, where tools snake through arteries to reach the heart, brain, and beyond.
Founded two decades ago and now led by Chairman & CEO David Leo Fischel, Stereotaxis is publicly traded, employs about 150 people in St. Louis, and its systems are used in roughly 100 hospitals globally. Over 150,000 patients have been treated using its technology.
From Wall Street to the Operating Room
Fischel didn’t start in a lab or hospital; his background is in medical device investing. But he was always drawn to the frontier where medicine meets engineering. “We like robots and we like medicine,” he says simply, and it shows. Under his leadership, Stereotaxis has poured years and tens of millions into developing a surgical robot that doesn’t just assist surgeons; it reimagines the tools themselves.
Why It’s Not Just Another Surgical Robot
Most surgical robots today operate like finely-tuned mechanical hands. That model works for open or laparoscopic surgeries, where tools are rigid and movements linear. But it breaks down when applied to endovascular procedures, where catheters must wind their way through a maze of vessels, sometimes narrower than a grain of rice.
The usual workaround? Robots that just hold the catheter a little more steadily. But Stereotaxis took a radically different approach: use magnetic fields to control the catheter tip directly, allowing millimeter-precise movement from outside the body. It’s like guiding a thread through a maze using invisible fingers.
A New Generation in the Works
So far, every one of those 150,000 plus patients has been treated using Stereotaxis’ first-generation technology. But that’s changing. The company has been investing heavily in three areas:
- Accessibility: Making the robot easy to install and remove, no more needing to remodel entire hospital rooms.
- Better Catheters: Creating devices that work across more procedures, from cardiac ablations to stroke treatments.
- Intelligence: Adding AI to guide physicians with real-time data and decision support.
Who Benefits
This isn’t just about top-tier hospitals or elite surgeons. The system helps physicians who might be cognitively sharp but less dexterous, a factor that becomes more relevant with age. And for patients, it means safer, more precise care with fewer complications. Fischel also points out that countries like the UK’s NHS, traditionally cost-conscious, are beginning to adopt robotics more aggressively, signaling a shift in mainstream acceptance.
The Big Picture
What frustrates Fischel most? The myopia. He compares the current moment to the early days of Intuitive Surgical, when people dismissed the Da Vinci robot as just a urology tool. “People often see only the initial use case,” he says. “They don’t recognize the platform potential.” He’s betting that Stereotaxis will do for endovascular surgery what Da Vinci did for laparoscopy, and he’s quietly laying the foundation to make that happen.
Where to Learn More
Stereotaxis is listed on the NYSE under the ticker STXS, and its website hosts a library of 500 plus clinical publications. Or, as Fischel offers with a smile, “If you’re ever in St. Louis, come by. We’ll show you how we build the robots.”
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
